Your browser is no longer supported. Please, upgrade your browser.
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E57.54 EPS (ttm)2.69 Insider Own0.40% Shs Outstand219.20M Perf Week1.17%
Market Cap33.96B Forward P/E10.77 EPS next Y14.39 Insider Trans-2.84% Shs Float218.93M Perf Month1.00%
Income603.40M PEG6.56 EPS next Q3.29 Inst Own91.30% Short Float3.56% Perf Quarter-0.48%
Sales6.07B P/S5.59 EPS this Y-74.60% Inst Trans-1.88% Short Ratio2.99 Perf Half Y23.68%
Book/sh53.15 P/B2.92 EPS next Y10.64% ROA3.40% Target Price172.00 Perf Year57.27%
Cash/sh13.69 P/C11.32 EPS next 5Y8.78% ROE5.40% 52W Range94.82 - 162.60 Perf YTD-0.79%
Dividend- P/FCF11.73 EPS past 5Y32.40% ROI4.30% 52W High-5.29% Beta1.27
Dividend %- Quick Ratio3.10 Sales past 5Y18.40% Gross Margin90.90% 52W Low62.41% ATR2.17
Employees3837 Current Ratio3.60 Sales Q/Q15.00% Oper. Margin10.40% RSI (14)52.01 Volatility0.97% 1.21%
OptionableYes Debt/Eq0.22 EPS Q/Q-39.50% Profit Margin9.90% Rel Volume0.33 Prev Close155.01
ShortableYes LT Debt/Eq0.21 EarningsFeb 04 BMO Payout0.00% Avg Volume2.61M Price154.00
Recom2.90 SMA200.53% SMA500.28% SMA20018.24% Volume177,419 Change-0.65%
Mar-23-21Downgrade SVB Leerink Outperform → Mkt Perform
Dec-16-20Downgrade Truist Buy → Hold $175
Dec-14-20Downgrade Wedbush Outperform → Neutral $175
Dec-14-20Downgrade Robert W. Baird Outperform → Neutral $175
Dec-14-20Downgrade Credit Suisse Outperform → Neutral $147 → $194
Dec-14-20Downgrade BMO Capital Markets Outperform → Market Perform $152 → $175
Oct-28-20Initiated UBS Neutral $133
Sep-01-20Resumed Stifel Hold $120 → $117
Jul-31-20Downgrade William Blair Outperform → Mkt Perform
Apr-28-20Initiated Cantor Fitzgerald Neutral $121
Mar-17-20Downgrade Oppenheimer Outperform → Perform
Mar-05-20Downgrade BofA/Merrill Buy → Neutral $130 → $110
Jan-31-20Resumed RBC Capital Mkts Outperform $135
Dec-17-19Downgrade Morgan Stanley Overweight → Equal-Weight $170 → $128
Nov-12-19Initiated SunTrust Buy $125
Oct-17-19Resumed BofA/Merrill Buy $130
Sep-26-19Initiated William Blair Outperform
Jul-31-19Resumed JP Morgan Overweight $172
May-23-19Resumed Goldman Neutral $142
May-23-19Resumed Citigroup Buy
Apr-12-21 01:17AM  
Apr-07-21 11:54AM  
Apr-06-21 11:50AM  
Apr-05-21 08:31PM  
Mar-30-21 08:18AM  
Mar-29-21 07:05PM  
Mar-26-21 02:08PM  
Mar-25-21 02:17PM  
Mar-20-21 03:11PM  
12:34PM  
Mar-19-21 09:45PM  
03:36PM  
Mar-17-21 08:22AM  
Mar-16-21 04:31PM  
Mar-13-21 01:32PM  
Mar-12-21 03:10PM  
Mar-10-21 11:17AM  
Mar-09-21 05:02PM  
Mar-06-21 11:31AM  
Mar-05-21 06:45PM  
07:00AM  
Mar-04-21 04:56PM  
Mar-01-21 12:04PM  
11:08AM  
08:00AM  
Feb-26-21 02:40PM  
Feb-22-21 08:33AM  
Feb-20-21 02:11PM  
Feb-19-21 04:15PM  
Feb-13-21 12:06PM  
Feb-12-21 12:12PM  
Feb-11-21 11:40AM  
10:30AM  
09:59AM  
07:57AM  
Feb-10-21 08:56AM  
Feb-06-21 11:52AM  
Feb-05-21 03:16PM  
02:06PM  
Feb-04-21 11:48AM  
09:25AM  
08:00AM  
Feb-03-21 08:43AM  
07:12AM  
Feb-02-21 10:00AM  
Feb-01-21 06:22AM  
Jan-30-21 05:03PM  
Jan-29-21 04:26PM  
09:31AM  
Jan-28-21 12:48PM  
12:32PM  
Jan-27-21 11:13AM  
Jan-26-21 11:40AM  
10:10AM  
Jan-25-21 04:05PM  
01:25PM  
Jan-22-21 04:48PM  
03:43PM  
11:44AM  
09:02AM  
Jan-21-21 05:20PM  
12:10PM  
07:14AM  
Jan-20-21 12:18PM  
12:13PM  
Jan-19-21 08:37AM  
Jan-15-21 10:30AM  
08:24AM  
Jan-14-21 04:43PM  
10:35AM  
06:31AM  
Jan-13-21 06:38PM  
04:20PM  
10:08AM  
Jan-12-21 07:00AM  
Jan-11-21 08:40AM  
Jan-07-21 01:55PM  
11:40AM  
Jan-06-21 04:54PM  
Jan-05-21 04:30PM  
11:26AM  
Jan-04-21 05:55PM  
Jan-02-21 08:09AM  
Jan-01-21 12:53PM  
Dec-31-20 06:00PM  
Dec-30-20 08:49PM  
Dec-24-20 10:59AM  
Dec-23-20 09:00PM  
01:30PM  
07:36AM  
Dec-21-20 07:56PM  
03:40AM  
Dec-19-20 02:15PM  
Dec-18-20 09:00PM  
Dec-16-20 07:45PM  
01:37PM  
01:01PM  
06:34AM  
Dec-15-20 07:45PM  
04:13PM  
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bazarko DanielSVP, Controller, CAODec 17Option Exercise117.0424,0662,816,74054,949Dec 21 05:00 PM
Bazarko DanielSVP, Controller, CAODec 17Sale157.7024,0663,795,23330,883Dec 21 05:00 PM
Carino TanishaEVP & CCAODec 03Sale122.261,530187,05816,102Dec 04 04:47 PM
Franchini Indrani LallEVP, Chief Compliance OfficerJun 08Sale114.696,853785,98128,218Jun 09 05:05 PM